Neutrophils in pancreatic cancer: Potential therapeutic targets

Wenkai Jiang1, Xin Li1†, Caifei Xiang2 and Wence Zhou1,3*

1The First Clinical Medical College, Lanzhou University, Lanzhou, China, 2The Second Clinical Medical College, Lanzhou University, Lanzhou, China, 3Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, China

Pancreatic cancer is a digestive system malignancy and poses a high mortality worldwide. Traditionally, neutrophils have been thought to play a role in acute inflammation. In contrast, their importance during tumor diseases has been less well studied. Generally, neutrophils are recruited into the tumor microenvironment and exert inflammation and tumor-promoting effects. As an essential part of the tumor microenvironment, neutrophils play diverse roles in pancreatic cancer, such as angiogenesis, progression, metastasis and immunosuppression. Additionally, neutrophils can be a new potential therapeutic target in cancer. Inhibitors of cytokines, chemokines and neutrophil extracellular traps can exert antitumor effects. In this review, we describe the role of neutrophils in the development and progression of pancreatic cancer, discuss their potential as therapeutic targets, and aim to provide ideas for improving the prognosis of patients with this malignant tumor disease.

KEYWORDS
anticancer therapy, neutrophil, neutrophil extracellular trap, pancreatic cancer, tumor-associated neutrophil

Introduction

The tumor microenvironment (TME) is a vital part of tumor formation, and TME homeostasis is regulated by signal transduction pathways and metabolism among tumor cells, endothelial cells, stromal cells and immune cells (1). Tumor growth can be modulated by the secretion of signaling molecules by immune cells, so in some cases tumor growth, invasion and metastasis can be regulated by the interactions between cancer cells and immune cells in the TME (2). Therefore, it is important to understand the relationships between cancer cells and the TME for the development of effective therapies. Traditionally, neutrophils have been thought to play a role in acute inflammation. Increased numbers of neutrophils enter tissues and kill microorganisms
by phagocytosis or the release of active substances from granules. Moreover, these cells can also cause severe damage to normal tissues (Figure 1). With increased knowledge of neutrophils, it has been found that neutrophils also participate in chronic inflammation, adaptive immune responses and tumor diseases (3, 4). Tumor-associated macrophages and fibroblast cells are involved in inflammation, which can support cancer progression (5). However, some evidence also suggests that neutrophils can be a new example of cancer-related inflammation and immunity (6, 7).

Pancreatic cancer is a malignancy and poses a serious medical trouble. In 2017, the number of pancreatic cancer cases worldwide was more than twice as high as in 1990. There was a 2.3-fold increase in the number of deaths from 196,000 in 1990 to 441,000 in 2017 (8). Despite progress in the available treatment methods and efficacy, pancreatic cancer patients have poor prognosis. Studies on the carcinogenic mechanism and the search for immune targets based on the TME have become directions in pancreatic cancer research, and tumor-associated neutrophils (TANs) provide new ideas.

In this review, we summarize the functions of neutrophils in pancreatic cancer development processes, such as angiogenesis, progression, metastasis, and immunosuppression. Next, we discuss the potential of neutrophils as anticancer therapeutic targets. We also propose future directions and how neutrophils may affect the therapeutic outcomes of pancreatic cancer patients, which may contribute to a new generation of anticancer therapies for pancreatic cancer patients.

Neutrophil life activity

Production, differentiation and death

Neutrophils account for 50-70% of circulating leukocytes in the human body (9). More than $10^{11}$ neutrophils may be produced each day (3). Human neutrophils have a half-life of approximately 8 hours in the circulation and are generally considered short-lived cells, but some studies have shown that the average circulating life of human neutrophils is 5.4 days (3, 10, 11). As hematopoietic stem cells differentiate in bone marrow, they first give rise to common myeloid progenitors, followed by granulocytes and monocytes. Granulocyte-colony stimulating factor (G-CSF), produced by bone marrow stromal cells, is a key cytokine that stimulates the production and mobilization of neutrophils in bone marrow (12). G-CSF regulates the differentiation of granulocyte-monocyte progenitor cells into neutrophils and the formation of myeloblasts. The subsequent stages of differentiation are promyelocytic, myelocyte, metamyelocyte, band cell and polymorphonuclear granulocyte (3). Mature neutrophils are released into the bloodstream and play roles in inflammation, infection, and chronic diseases in the body.

There are protective mechanisms to balance the number of neutrophils so that these cells do not become overactive in blood vessels and cause severe damage to normal tissues. The bone marrow is also a site at which circulating neutrophils are recycled. Neutrophil release is negatively regulated by CXC-
Chemokine receptor 4 (CXCR4) signaling in a cellular autonomous manner (13). In the bone marrow, senescent neutrophils are removed via a CXCR4-dependent process. Neutrophils are reassigned from the bone marrow to the blood when CXCR4 signaling is lost (14). In addition, liver Kupffer phagocytosis functions and regulation of the microbiome also limit over the numbers of neutrophils (15, 16). Neutrophils are often activated by a two-step process of priming followed by activation, which avoids non-specific triggering of their cytotoxic mechanisms, and undergo rapid apoptosis which blocks their ability to respond to extracellular ligands (17, 18). Thus, these mechanisms by which both the number and activation of neutrophils are tightly controlled in the circulation ensures that the human body is protected against microbial pathogens and reduces damage to its own tissues.

Neutrophil recruitment

Neutrophil recruitment begins with changes in endothelial cells and processing including tethering, rolling, adhesion, crawling and, finally, transmigration (4). After neutrophils reach the vascular edge, their rolling process is dependent on selectin, and the adhesion process is dependent on integrin, which results in the tight adherence of neutrophils to endothelial cells (19, 20). Platelet endothelial cell adhesion molecule is expressed on the neutrophil surface and endothelial cell surface, promoting neutrophil migration out of the vascular endothelium by mediating the binding of these two cells (21). Then neutrophils secrete molecules such as collagenase to degrade the vascular basement membrane but preferentially they move through membrane regions with low expression of extracellular matrix components, and then enter the surrounding tissues (4). Then, neutrophils migrate between pericytes, crawl along the cells through intercellular signals and search for gaps through which they can finally leave the vasculature. After extravasation, neutrophils make directional movements along the chemical concentration gradient and accumulate in inflammatory sites.

Chemokines, such as CXCR1, CXCR2 and CXCR4, are critical in neutrophil recruitment (4, 22, 23). In addition, cytokines such as interleukins (ILs) and tumor necrosis factors (TNFs), and intracellular proteins such as poly ADP-ribose polymerase 1, cathepsin C and S100 calcium-binding protein A9 can also increase neutrophil activation and recruitment (24–27). Prolongation of the neutrophil lifespan can further enhance their functional roles. Although the normal lifespan of neutrophils is short, certain cytokines and bacterial products can prolong neutrophil survival by interfering with apoptosis. For instance, G-CSF can delay neutrophil apoptosis by inhibiting the activation of calpain, a calcium-dependent cysteine protease that is upstream of caspase-3, resulting in a delay in apoptosis of approximately 12 hours (28, 29).

Neutrophils and cancer

Circulating neutrophils

Serological indicators are widely used to predict the overall survival (OS, a term that denotes the time of staying alive for individuals that suffer from a specific disease) of tumor diseases due to their advantages of simplicity, economy and noninvasiveness (30). As a marker of systemic inflammation, the neutrophil/lymphocyte ratio (NLR) is currently an attractive biomarker for risk stratification and guiding treatment decisions in cancer patients (31).

Especially in early-stage pancreatic ductal adenocarcinoma (PDAC), finding biomarkers to predict recurrence can lead to a better prognosis. The NLR is associated with the tumor stage, and patients with PDAC whose tumor stages were less than IIA had longer OS and recurrence-free survival (RFS, time from surgery to the date of first recurrence) when the NLR > 2.2 (hazard ratio =3.310, 95% confidence interval: 1.259-8.745). However, the NLR was not associated with OS or RFS in patients with tumor stage greater than IIB (32). Since only a few pancreatic cancer patients have surgical indications at the time of diagnosis, it is important to construct accurate prognostic models in patients with unresectable pancreatic cancer. The NLR is better than other serological indicators (such as the platelet/lymphocyte ratio and prognostic nutritional index) among prognostic factors in nonsurgically resectable pancreatic cancer patients after 6 months of follow-up. Multivariate analysis showed that a high NLR (HR=2.430, 95% CI: 1.484 to 3.977) is an independent predictor of OS (33).

The NLR can also predict how pancreatic cancer will respond to drug treatment. In retrospective studies of pancreatic cancer patients treated with FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, 5-fluorouracil) and immune checkpoint inhibitors, a high NLR was associated with poor prognosis (34, 35).

Neutrophil extracellular traps (NETs)

NETs are formed by the release of cellular contents by activated neutrophils into surrounding tissues or circulation (36). Neutrophils can be stimulated to produce NETs by a variety of substances, including bacteria, viruses and some chemical or biological factors (37). Chemokines in the TME, such as IL-8, can promote the formation of NETs and help recruit more neutrophils (38). Conversely, NETs can also promote tumor growth and have a positive effect on the TME, including enhancing mitochondrial function in tumor cells, blocking the function of immune cells and exhibiting angiogenic activity by increasing capillary length, loop number, and tubule area (39, 40). Thus, NETs can accelerate tumor growth and cause tumor immune escape.
Based on the putative role of NETs in the TME, NETs may have potential as a biomarker for prognosis of some cancer patients. For example, the level of NETs is increased in cancer patients and is significantly higher in patients with advanced stage disease than in patients with early disease (41). In patients with pancreatic cancer, NET was an independent prognostic factor for OS (HR=2.366, 95% CI: 1.408–3.978) and RFS (HR=3.037, 95% CI: 1.809–5.098) and could predict the survival of patients who received gemcitabine-based chemotherapy (42). At present, NETs were confirmed to be involved in the biological process of pancreatic cancer in some preclinical studies. NETs-mediated metastasis and drug resistance of cancer cells will provide new insights into anticancer therapies.

TANs and cancer diseases

TAN can be involved in the progression of tumor disease. A meta-analysis showed that the level of intratumoral neutrophils was independently associated with OS and RFS in cancer patients (43). In the TME, TANs can take an antitumorigenic and pro-tumorigenic phenotype (44). Cytokines in the TME impacts on the balance of these two subpopulations. For instance, TAN can become the “promoting the tumor” type in response to transforming growth factor-β (TGF-β) (45). Neutrophil with this phenotype can produce pro-tumor factors (6). By contrast, low doses of interferon-β induced neutrophil to polarized to the “antitumor” phenotype in C57BL/6 and BALB/C mice, and similar changes were also observed in melanoma patients treated with type I interferon (46). “Antitumor” phenotype TANs produce chemokines, such as CCL3, CXCL9, CXCL10, to recruit CD8+ T cells to the TME (47). There is also evidence that they can increased cytotoxicity and reduced immunosuppression by the production of TNF-α, ROS and CD95, thus providing anticancer effect (48, 49).

The diversity of neutrophils leads to their dual potential in the TME. As a part of tumor-associated inflammation, TANs are involved in tumor growth and metastasis. Additionally, neutrophils can interact with other immune cells and stromal cells, resulting in extracellular matrix accumulation and immune function changes (50). In mouse models, TANs mediate the infiltration of regulatory T (Treg) cells and macrophages in the TME by secreting the chemokines CCL2 and CCLI7, leading to the growth of hepatocellular carcinoma cells and increasing the resistance of hepatocellular carcinoma patients to sorafenib (51). In colorectal cancer, tumor growth is related to the gut microbiome because these tumor cells produce IL-17 and mediate the inflammatory response (e.g., driving B-cell infiltration). Neutrophils can limit the number of microorganisms and the expression of IL-17 to reduce inflammation related to tumor progression (52). Conversely, neutrophils can also mediate antitumor responses (50). IL-1β and IL-1β signaling in neutrophils enhances the antimicrobial activities in colorectal cancer, which inhibits bacterial-driven inflammation and alleviated tumorigenesis (53). Hepatocyte growth factor (HGF) acts on the HGF receptor expressed on neutrophils and promotes the production of inducible nitric oxide synthase (iNOS); iNOS releases nitric oxide and promotes apoptosis of tumor cells (54).

Carcinogenic mechanisms of neutrophils in pancreatic cancer

As we mentioned earlier, TANs participate in various cancer-related processes in the TME and are associated with poor prognosis for most cancers. In this section, we will introduce how TANs promote the progression of pancreatic cancer, such as through angiogenesis, pancreatic cancer cell metastasis and immune suppression. A deep understanding of these mechanisms will not only enable us to understand the promoting effect of the TME on pancreatic cancer, but also provide us with new therapeutic targets.

TANs and angiogenesis

Angiogenesis is a critical link in tumor growth and metastasis, and it is jointly regulated by tumor cells, stromal cells and their bioactive products, such as various growth factors and extracellular matrix (55). Activated neutrophils release multiple angiogenic factors, including vascular endothelial growth factors (VEGFs), CXCLs and matrix metalloproteinases (MMPs), and form NETs (56).

Histones, which are major components of NETs, significantly increased vascular endothelial tubule formation in a dose-dependent manner (57). After treatment with 100 IU/mL heparin and 62.5 μg/mL polysialic acid for 1 hour, the histone-induced production of tubules in vascular endothelial cells was inhibited. This effect occurred because heparin and polysialic acid are anionic substances that bind to positively charged histones and neutralize their activity (57).

MMP plays an important role in angiogenesis, and MMP-9 promotes the release of VEGF from the extracellular matrix and participates in the interaction between VEGF and VEGF receptors (58). Neutrophils can be a source of MMP-9 in tumor angiogenesis (59). The addition of neutrophils to pancreatic cancer cells can increase the budding rate by more than 2.5 times because MMP-9 may promote endothelial cell migration. After 14 days of treatment with bevacizumab (a VEGF inhibitor) and doxycycline (a drug which could inhibit angiogenesis as effectively as MMP-9 inhibitors), the tumor volume in pancreatic cancer mice was significantly reduced. Furthermore, the average vascular density of pancreatic cancer mice was also significantly reduced (60). Therefore, MMP-9
produced by neutrophils may be a therapeutic target in pancreatic cancer treatment and provide a feasible alternative treatment for pancreatic cancer patients.

Neutrophil gelatinase-associated lipocalin (NGAL) is secreted by neutrophils and is upregulated in a variety of tumor diseases (61). NGAL can potentially inhibit angiogenesis by reducing VEGF production in pancreatic cancer cells. Compared with that in the control groups, adding NGAL reduced the tube formation of human umbilical vein endothelial cells (HUVECs) in MIA PaCa-2 (RRID: CVCL_0428) and PANC-1 (RRID: CVCL_0480) (two pancreatic cancer cell lines) cells by 69.5% ± 5% and 68% ± 7.5%, respectively (62). Moreover, CXCL5 mediates pancreatic cancer angiogenesis in mouse model by activating multiple signaling pathways, including signal transducer and activator of transcription pathways and extracellular signal-regulated kinase pathways in human endothelial cells (63). Due to the important role of neutrophils in tumor angiogenesis, neutrophil suppression may be an effective anticancer strategy.

Progression and metastasis

TANs are involved in tumor progression and migration. As early as 1989, neutrophils were shown to promote lung metastasis of breast cancer (64). TNF, leukotriene B4 and IL in the TME play roles in tumor progression and metastasis influenced by neutrophils (6).

In normal pancreas tissue, obesity promotes the inflammatory response and fibrosis; in pancreatic cancer, cytokines produced by dysfunctional fat cells, such as IL-1β, increase pancreatic stellate cells (PSC) activation and recruit TANs (65). PSCs are the main cell type in the pancreatic cancer stroma, and their large presence suggests that they may contribute to the metabolism of cancer cells (66). TANs also secrete IL-1β, which is involved in PSC activation, immunosuppression and PDAC progression. Moreover, adjuvant chemotherapy showed no significant survival advantage in overweight and obese patients with PDAC. Thus, the cross interaction between adipocytes, TANs and PSCs promotes the progression of PDAC, with IL-1β playing a major role in this process (65).

The purinergic receptor P2RX1, an ATP-gated ion channel, is associated with the inflammatory activation of immune cells (67). A large number of P2RX1-deleted neutrophils were found in the hepatic metastasis model of PDAC. The immune response of P2RX1 negative neutrophils in the PDAC TME is characterized by elevated MMP-9. The metabolic characteristics were a significant increase in the oxygen consumption rate and a nonsignificant increase in the extracellular acid rate (decreased glycolysis in neutrophils and enhanced oxidative phosphorylation in mitochondria). This effect occurs because the deletion of P2RX1 can increase the activity of the neutrophil transcription factor NF-E2 p45-related factor 2 (NRF2) (68). NRF2 is critical in regulating redox, metabolic, protein homeostasis, and inflammation (69). Increased NRF2 activity contributes to the metabolic reprogramming of neutrophils during polarization. Second, NRF2 directly regulates PD-L1 transcription and has a direct impact on CD8+ T-cell failure (68). Because Nrf2 is critical for immunosuppressive microenvironment formation in pancreatic cancer liver metastases via shaping the immunosuppressive phenotypes of P2RX1-negative neutrophil, future therapy, such as inhibiting the specific gene to reduce the particular phenotype of neutrophil subpopulation, may help treat pancreatic cancer.

NET formation is dependent on receptor for advanced glycation end products (RAGE) and autophagy pathways and is mediated by citrullination of histones to allow DNA expulsion from cells. Inhibition of autophagy by chloroquine or ablation of RAGE resulted in decreased NET formation (70). NETs can enhance tumor migration and invasion by inducing epithelial cells to transform into mesenchymal cells. Moreover, neutrophils can degrade E-cadherin on pancreatic cancer cells by secreting elastase, leading to increased tumor cell migration and invasion, and resulting in PDAC progression and metastasis (71). The effects of neutrophils on the progression and metastasis of pancreatic cancer are summarized in Figure 2.

TANs and immunosuppression

The TME has the ability to regulate immunosuppression, and understanding the mechanisms by which pancreatic cancer cells evade tumor immunity is crucial for developing more effective therapies. NETs can promote tumor growth and metastasis through a variety of mechanisms: trapping circulating tumor cells and protecting them, thereby preventing T cell and natural killer cell-mediated cytotoxicity (56).

CXCL5, a CXCR2 ligand, are significantly elevated in pancreatic cancer and can recruit TANs. This process is regulated by the activity of the NF-κB signaling pathway in mouse models, suggesting that neutrophils are involved in pancreatic cancer inflammation. Reducing CXCR2 significantly inhibited the number of TANs in pancreatic cancer, leading to spontaneous, T-cell-dependent tumor growth inhibition (72). Because the CXCR2 ligand axis is involved in the recruitment of TANs and the regulation of T-cell immunity in pancreatic cancer, it is expected to be a potential therapeutic target for pancreatic cancer.

Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are both signaling molecules commonly seen on activated T cells, and have been found to be effective immunotherapeutic targets in cancer (73). IL-17 is highly expressed in tumor tissues. After treatment with IL-17, several chemokines capable of recruiting neutrophils were significantly induced. Researchers found that IL-17 signaling favors CD8+ T-cell inactivation and significantly affects immune
checkpoint blockade (PD-1, CTLA-4) sensitivity. However, inhibition of neutrophils neutralizes IL-17. Thus, IL-17 promotes immunosuppression and resistance to immune checkpoint blockade by inducing neutrophil infiltration in pancreatic cancer (74).

Heterogeneous myeloid-derived suppressor cells (MDSCs) are suppressors of antitumor immunity, making tumor immunotherapy difficult. MDSC can inhibit T cell and NK cell proliferation and promote the function of Treg cells by secreting TGF-β and IL-10; moreover, MDSC can release reactive oxygen species and cause damage to the infiltrating lymphocytes in the TME (75). Neutrophil-like MDSCs (nMDSCs) are significantly increased in PDAC. The expression of high levels of CD13 on nMDSCs more effectively suppresses antitumor immunity through an arginase-1-related mechanism and PDAC patients with higher CD13 expression have a shorter OS (76).

Currently, there have been few studies on the specific mechanism by which TAN indirectly promotes immunosuppression. TANs can promote the recruitment of Tregs to the TME through the release of the chemokine CCL17, leading to the formation of an immunosuppressive microenvironment (77). A link between TANs and other immunosuppressive cell types acting together to impair antitumor immunity in pancreatic cancer needs to be further studied in the future. The interactions between neutrophils and other cells in the pancreatic cancer TME are summarized in Table 1.

**Neutrophils as therapeutic targets**

Gemcitabine, which produces anticancer activity by interfering with DNA synthesis in cancer cells, has been the most important chemotherapy drug for patients with pancreatic cancer in the past two decades (78). Due to the poor efficacy of chemotherapeutic drugs in some patients, new clinical treatment strategies are increasingly accepted in the treatment of pancreatic cancer. At present, targeted therapy and immunotherapy is representative of a new generation of cancer therapies, and is also the focus of pancreatic cancer research (79). The exploration of the biological function of immune cells in the tumor microenvironment will lead to more effective therapies to suppress the inflammatory response of the TME using cytokine inhibitors, chemokine inhibitors and immune checkpoint inhibitors to enhance anticancer immunity. TAN targeted therapies have been validated in human cancers (80).
Additionally, objective response rate, disease control rate, and the disease control rate was 34.5% in the evaluable population.

Cytokine inhibitors

Cytokines are key mediators of cell signaling in the TME (90). Recently, cytokines and cytokine receptors have received extensive attention as targeted therapies for cancer, mainly by inhibiting pro-inflammatory cytokines and pro-tumor cytokines (91). As mentioned above, cytokines in the TME can induce neutrophil differentiation and prolong the lifespan of neutrophils. Therefore, inhibition of these cytokines to prevent neutrophils from differentiating into pro-tumor phenotypes is also one of the current targeted therapies.

TGF-β promoted the differentiation of neutrophils into a pro-tumor phenotype. TGF-β inhibitors mainly target the serine/threonine kinase domain of TGF-β receptor 1; for
instance, galunisertib in vivo in combination with immune checkpoint inhibitors can significantly inhibit the growth of pancreatic cancer and enhance the antitumor M1 macrophage infiltration in the TME (92, 93). In current phase I B and phase II trials, galunisertib has also shown good tolerability, safety and antitumor activity in unresectable pancreatic cancer (NCT02734160) (94, 95). Selecting predictive biomarkers of TGF-β inhibition in pancreatic cancer patients may be more effective in predicting treatment effect and patient prognosis.

IL-17 can recruit neutrophils and form NETs that reduce cytotoxic CD8+ T cells in the pancreatic cancer TME (74). In mice with IL-17 overexpression, antibodies to IL-17 and IL-17 receptors reduce pancreatic intraepithelial neoplasia and neutrophil infiltration, and antibodies to IL-17 and IL-17 receptors are currently in clinical trials (96, 97).

G-CSF plays an important role in the activation and mobilization of neutrophils. Lorlatinib is a novel, oral tyrosine kinase inhibitor with anticancer activity in ALK- or ROS1-positive cancer patients (98). Lorlatinib prevents G-CSF and GM-CSF from inducing neutrophil migration. In PDAC, lorlatinib specifically targets neutrophils to inhibit cancer cells by regulating the development of neutrophils in bone marrow cells, reducing the accumulation of neutrophils in the TME, and inhibiting tumor tissue fibrosis. When lorlatinib is combined with anti-PD-1, the number of CD8+ T cells increases and CD44+, CD69+, CD8+ T cells are activated, suggesting that lorlatinib improves the response of PDAC to immunotherapy (99). Similarly, a combination of suppressing cytokines that promote neutrophil recruitment and blocking immune checkpoints has been demonstrated in several preclinical trials. For instance, combination of anti-CSF1 receptor, anti-PD-1 and gemcitabine decreased the infiltration of myeloid cells and improved the antitumor effect (100). Some clinical trials that evaluating the safety and activity of cytokine inhibitors combined with immune checkpoint inhibitors are ongoing (NCT02947165, NCT04581343, NCT02777710).

**Inhibition of NETs**

NETs are now considered a promising cancer treatment target. Because NETs are involved in angiogenesis,
immosuppression and metastasis of cancer, inhibiting their formation or promoting their elimination has been proposed as a novel therapeutic strategy for cancer (46, 56). There are two main methods to inhibit NET: inhibiting the formation of NET and destroying the structure of NET. NET formation is mediated by peptidyl arginine deiminase 4 (PADI4) and elastase, in which PADI4 promotes the expulsion of chromosomes via histone citrullination, but berberine can inhibit PADI4 expression in vitro (101, 102). In PADI4-deficient mice, pancreatic cancer growth was shown to be restricted (103). Cancer cells can also release exosomes to stimulate NET formation. Exosomes play a role in intercellular communication by transferring intracellular substances such as proteins, metabolites and nucleic acids to recipient cells (104). Cancer-derived exosomes can transfer factors related to cancer progression and promote tumorogenesis by regulating proliferation, metastasis, immune escape and increasing drug resistance processes (105). Studies have shown that cancer-derived exosomes transfer mutant KRAS to neutrophils, thereby promoting NET formation by upregulating IL-8 (106). Therefore, inhibition of exosome release in the TME is also a potential antitumor strategy.

Suppressing the components of NETs is also one of the strategies for targeting NETs. Serum DNA and citrullinated histone H3 are markers of NET formation. DNase is considered a promising cancer treatment for its ability to degrade circulating free DNA, thereby destroying the structure and function of NET (107). In a preclinical model of pancreatic cancer, the use of DNase I significantly reduced the number of fibroblasts accumulated in liver metastases, thereby attenuating NET-induced cancer invasion and metastasis (108). Thrombomodulin protein can degrade NET-derived high mobility group box 1 through thrombin, thereby inhibiting NET-induced epithelial-mesenchymal transformation and preventing the invasion and metastasis of pancreatic cancer cells (71).

Chloroquine is also a candidate to inhibit NETs. Chloroquine destroys the structure of NETs by inhibiting autophagy of glycosylated end-product receptors in pancreatic cancer (70). A meta-analysis evaluating the clinical value of using chloroquine as an autophagy inhibitor in the treatment of cancers showed that autophagy inhibitor therapy significantly improved the objective response rates, OS and progression-free survival of cancer patients, suggesting that the role of chloroquine in the treatment of pancreatic cancer should also be explored (109).

Additionally, gentamicin inhibits NETs release from human neutrophils and reactive oxygen species inhibitor (diphenyleneiodonium chloride) also reduces NET formation in a concentration-dependent manner (110, 111). These drugs are expected to be further validated the ability to inhibit NETs.

### Treatment of complications and comorbidities for pancreatic cancer

Pancreatc cancer patients often have different diseases or complications in which neutrophils play different roles. Pancreatic cancer patients are in hypercoagulable state, which is directly related to poor prognosis and venous thrombosis (112–114). Citrullinated histone H3 is one of the markers of NETs, and increased expression of citrullinated histone H3 was observed in the thrombi of pancreatic cancer mice. The thrombus weight decreased after using IAB, an anti-LY6G antibody, to deplete neutrophils and DNase I to deplete NETs (115). Chloroquine inhibits NET formation and reverses NET-mediated platelet activation and aggregation, as well as tissue factor release. Researchers further found that the rate of venous thromboembolism in patients treated with hydroxychloroquine was 9.1%, while that in the control group was 30% (70, 116).

Neutrophil infiltration was increased in pancreatic cancer specimens from patients with type 2 diabetes mellitus (T2DM). Patients with elevated neutrophils had reduced OS (HR=5.44, 95% CI 1.12 to 26.34) (117). Anorexia and muscle breakdown induced by PDAC are also associated with inflammatory stimulation of neutrophils mediated by the CCR2/CCL2 axis (118). Inflammatory processes and immune system contribute to the metabolic diseases (119, 120). Therefore, based on the role of neutrophils in pancreatic cancer and metabolic disease, such as T2DM, inhibition of neutrophils can simultaneously alleviate the progression of both diseases. Combination therapeutic strategy involving multiple immunomodulatory therapies may prove to be more effective.

### Other potential therapeutic targets

Tumor genotypes can affect the TME and play a key role in treatment resistance. In gain-of-function Trp53 mutant mouse, intratumoral neutrophil infiltration increased and the numbers of CD3+ T cells, CD4+ T cells and CD8+ T cells decreased. After neutrophil removal, the sensitivity of CD40 agonists combined with chemotherapy and immunotherapy was enhanced (121).

Several bioinformatics analyses have shown a significant correlation between oncogene expression and the infiltration of various immune cells, including neutrophils, suggesting that targeting these genes may also be a future therapy (122).

Chemotherapy induces the invasion of cytotoxic T cells into the liver metastases of pancreatic cancer, but only briefly. Neutrophils lead to tumor cell regeneration in metastases, and reducing neutrophil infiltration or inhibiting the Gas6/AXL signaling axis combined with chemotherapy can inhibit metastatic growth (123).
MDSCs are sensitive to TRAIL receptor 2 agonists. The antitumor efficacy of DS-8273A (an anti-TRAILR2 antibody) was evaluated in a phase I clinical trial (including one pancreatic cancer patient). The results showed that DS-8273A eliminated polymorphonuclear MDSCs (PMN-MDSCs, immature neutrophils) and prolonged progression-free survival (124). STAT3 is involved in the regulation of arginase 1 activity in PMN-MDSCs, leading to immunosuppression in the TME. Inhibition of STAT3 or using human recombinant arginase 1 (PEG5000) may be beneficial to ameliorate this immunosuppressive microenvironment (125, 126).

**Areas of future development**

Finding novel therapies is currently a hot spot and future research direction for cancer research. As an indispensable part of tumor development, the TME has become a new therapeutic target. Based on the important role of neutrophils in the TME of pancreatic cancer, it is feasible to target neutrophils in the treatment of pancreatic cancer.

**Limitation**

There are still some challenges in the treatment of pancreatic cancer patients based on neutrophil-related oncogenic mechanisms. First, specific reductions of neutrophils in peripheral blood and the TME can inhibit tumor growth and metastasis but can expose patients to opportunistic infections. Since cancer patients often suffer from malnutrition, cachexia, and reduced resistance, such treatments are impractical. Next, blocking chemokines and cytokines also affects the recruitment and function of “antitumor phenotype” neutrophils and other leukocytes, resulting in the limited specificity of currently conducted approaches. Thus, only a few studies have focused on the effects of drugs on specific TAN phenotypes. Moreover, most of the drugs that regulate the TME and target TANs have been studied in animal experiments, but clinical evidence in solid tumor patients is insufficient. Although there have been pilot studies showing a substantial anticancer effect of neutrophil-targeting inhibitors, these need to be followed by more clinical trials so that targeting neutrophil-associated sites or specific phenotypes can be a new treatment for patients with pancreatic cancer. There is also a need for studies that investigate the adverse effects of targeting neutrophils in pancreatic cancer.

**Improved future direction**

The pancreatic cancer TME is a complex and dynamic structure that directly affects the biological behavior of pancreatic cancer cells at the molecular and clinical levels. Current work focuses on interactions among tumor cells, neutrophils and inflammatory factors. We should study the following aspects in the future.

First, extracellular vesicle-mediated signal transduction between pancreatic cancer cells and immune cells should be intensively studied. Extracellular vesicle can help facilitate an exchange of information within various cells in the TME (127). It has been found that extracellular vesicle-RNA and proteins are involved in the metastasis and chemotherapeutic resistance of pancreatic cancer (128). Inhibition of extracellular vesicle release and uptake in the TME may be another therapeutic option. Second, although immune checkpoint inhibitors have made progress in cancer treatment during the past 10 years, they are only effective in a subset of patients. Since neutrophils can induce the TME to form an immunosuppressive microenvironment, this may be one of the reasons for the poor efficacy of immune checkpoint inhibitors in pancreatic cancer. Therefore, the combination of neutrophil inhibitor therapy and immune checkpoint inhibitor therapy also needs more preclinical studies and clinical trials in the future. Furthermore, cellular metabolism has also emerged as a critical determinant of the function of immune cells in the TME. The metabolism of substances in the TME is not only the result of tumor development, but also the promoting factor of tumor progression (129). A subpopulation of TANs with high glycolytic activity has been found to enhance immunosuppressive and tumor-promoting functions (130). Understanding the metabolic requirements of neutrophils in pancreatic cancer and their effect on the growth, metastasis and immunosuppression of pancreatic cancer will also be a novel research direction upon which to intervene for enhanced immunotherapy.

**Neutrophils in pancreatic inflammation and fibrosis**

Since pancreatic cancer is closely related to pancreatic chronic inflammation and fibrosis, it is necessary to explore the role of neutrophils in the process of chronic pancreatic fibrosis. Immune cells, especially myeloid cells, play an important role in the pathogenesis of pancreatitis. GM-CSF-mediated increased neutrophil infiltration is the main reason that STAT5 promotes pancreatic fibrosis and chronic pancreatitis (131). However, CXCR2 inhibitors reversed pancreatic inflammation in vivo models (132). It is also one of the future directions to conduct joint research with related chronic diseases in cancer mechanistic studies (89). Therefore, it is important to combine pancreatic cancer and chronic pancreatitis in animal models when doing preclinical studies. Including patients with chronic pancreatitis as a
comparison group is also necessary when conducting clinical trials.

Conclusion

Neutrophils play a role in angiogenesis, metastasis and immunosuppression in pancreatic cancer through interactions with other cells in the TME. Various neutrophil modulation therapies are entering preclinical studies and clinical trials for pancreatic cancer. Precision medicine aims to provide patients with more effective personalized medical services (133). The treatment mode of pancreatic cancer is gradually developing toward targeted therapy and precision medicine. The research and development of neutrophil-based therapeutics and targeting neutrophils in combination with other therapies will benefit more patients with pancreatic cancer. Specifically targeting neutrophil-associated sites will be part of therapies for the next generation of cancer patients.

Author contributions

WJ, XL, and WZ contributed to the study conception and design. The original draft of the manuscript was written by WJ and XL. WJ and XL contributed to visualization. Review and editing was performed by CX and WZ. WZ provided language help. All authors contributed to manuscript revision, read, and approved the submitted version.

References

1. Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer (2021) 21:71–88. doi: 10.1038/s41568-020-00312-2
2. Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab (2021) 3:21–32. doi: 10.1038/s42255-020-00317-z
3. Borregaard N. Neutrophils, from marrow to microbes. Immunity (2010) 33:657–70. doi: 10.1016/j.immuni.2010.11.011
4. Kolaczkowska E, Kubis P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol (2013) 13:159–75. doi: 10.1038/nri3399
5. Buechler MB, Fu W, Turley SJ. Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer. Immunity (2021) 54:903–15. doi: 10.1016/j.immuni.2021.04.021
6. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer (2016) 16:431–46. doi: 10.1038/nrc.2016.52
7. Shald ME, Friedlander ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol (2019) 16:601–20. doi: 10.1038/s41571-019-0222-4
8. GBD 2017 Pancreatic cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol (2019) 4:934–47. doi: 10.1016/S2542-1251(19)30347-4
9. Eruslanov EB, Singhal S, Albeda SM. Mouse versus human neutrophils in cancer: A major knowledge gap. Trends Cancer (2017) 3:149–60. doi: 10.1016/j.trecan.2016.12.006
10. Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, Bogaerts JA, et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood (2010) 116:265–7. doi: 10.1182/blood-2010-01-259028
11. Galli SJ, Borregaard N, Wyn TA. Phenotypic and functional plasticity of cells in innate immunity: macrophages, mast cells and neutrophils. Nat Immunol (2011) 12:1035–44. doi: 10.1038/ni.2109
12. Martin KR, Wong HL, Witsa-Sarsat V, Wicks IP. G-CSF - a double edge sword in neutrophil mediated immunity. Semin Immunol (2021) 54:101516. doi: 10.1016/j.smim.2021.101516
13. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/Il2Rg(null) mice. Leukemia (2002) 16:1992–2003. doi: 10.1038/sj.leu.2402684
14. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood (2009) 113:4711–9. doi: 10.1182/blood-2008-09-177287
15. Shi J, Gilbert GE, Kobuko Y, Ohashi T. Role of the liver in regulating numbers of circulating neutrophils. Blood (2001) 98:1226–30. doi: 10.1182/blood.V98.4.1226
16. Zhang D, Chen G, Manwani D, Mortho A, Xu C, Faith JJ, et al. Neutrophil ageing is regulated by the microbiome. Nature (2015) 525:528–32. doi: 10.1038/nature15367
17. Mol S, Hafkamp FMJ, Varela L, Simkhada N, Taanman-Kueter EW, Tas SW, et al. Efficient neutrophil activation requires two simultaneous activating stimuli. Int J Mol Sci (2021) 22:10106. doi: 10.3390/ijms221810106
Funding

This work was supported by the Science and Technology Projects of Chengguan District in Lanzhou, China (2020-2-11-4) and the Traditional Chinese Medicine Scientific Research Project of Gansu Province, China (GZKP-2020-28).

Acknowledgments

The authors would like to express their gratitude to AJE (www.aje.com) for the expert linguistic services provided.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
18. Pérez-Figueroa E, Álvarez-Carrasco P, Ortega E, Maldonado-Bernal C. Neutrophils: Many ways to die. Front Immunol (2021) 12:638122. doi: 10.3389/fimmu.2021.638122

19. Zarbick A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood (2011) 118:6743–51. doi: 10.1182/blood-2011-07-345566

20. Cunningham BP, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol (2011) 3:a004994. doi: 10.1101/cshperspect.a004994

21. Ley K, Ladhanna C, Cybulsky ML, Noursough S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol (2007) 7:678–89. doi: 10.1038/nri2156

22. Timascian C, Vogel GFA, Orec C, Vetter D, Durochat C, Chinal C, et al. Pivotal role for Cxcr2 in regulating tumor-associated neutrophil in breast cancer. Cancers (Basel) (2021) 13:2584. doi: 10.3390/cancers13112584

23. Metzetzeakers M, Gouwey M, Froost P. Neutrophil chemotactant receptors in health and disease: double-edged swords. Cell Mol Immunol (2020) 17:433–50. doi: 10.1042/cim02130-0412-n

24. Wu L, Awaji M, Saxena S, Varney ML, Sharma B, Singh RK. IL-17-CXCL12 chemokine receptor 2 axis facilitates breast cancer progression by up-regulating neutrophil recruitment. Am J Pathol (2020) 190:222–33. doi: 10.1016/j.ajpath.2019.09.016

25. Wang S, Yang FL, Wang X, Zhou Y, Dai Y, Han B, et al. PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization. Oncotarget (2017) 8:88918–33. doi: 10.18632/oncotarget.21449

26. Xiao Y, Cong M, Li J, He D, Wu Q, Tian P, et al. Cathepsin p promotes breast cancer breast metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. Cancer Cell (2021) 39(4):433–47. doi: 10.1016/j.ccell.2021.02.012

27. Sun F, Zhang H, Huang T, Shi J, Wei T, Wang Y. S100A9 blockade improves the functional recovery after spinal cord injury via mediating neutrophil infiltration. Exp Ther Med (2022) 23:291. doi: 10.3892/etm.2022.11220

28. van Raam BJ, Drewniak A, Groenewold V, van den Berg TK, Kuijpers TW. Neutrophil extracellular traps produced during inflammation in mice and human. Exp Ther Med (2022) 23:291. doi: 10.3892/etm.2022.11220

29. Colotta F, Re F, Polentarutti N, Sozanni S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood (1992) 80:2012–20. doi: 10.1182/blood.V80.8.2012

30. Driscoll J, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J (2009) 15:401–5. doi: 10.1665/PP09-0318.Ric2d0

31. Templeton AJ, McNamara MG, Sruga B, Vera-Badillo FE, Aneja P, Ochana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst (2014) 106(6):djw124. doi: 10.1093/jnci/djw124

32. Abe T, Amano H, Kobayashi T, Hanada K, Nakahara M, Ohdan H, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma. Eur J Surg Oncol (2018) 44:1573–9. doi: 10.1016/j.ejso.2018.04.022

33. Iwai N, Okuda T, Sakagami J, Harada T, Ohara T, Taniguchi M, et al. Neutrophil extracellular traps, angiogenesis and cancer. Biomedicines (2022) 10:838133. doi: 10.3389/fphar.2022.838133

34. van Gisbergen KP, Geijtenbeek TB, van Kooyk Y. Close encounters of neutrophils and DCs. Trends Immunol (2005) 26:626–31. doi: 10.1016/j.itt.2005.09.007

35. Mizuno R, Kawada K, Itatani Y, Ogawa R, Kiyasu Y, Sakai Y. The role of tumor-associated neutrophils in colorectal cancer. Int J Mol Sci (2019) 20:529. doi: 10.3390/ijms20050529

36. Jaillon S, Ponzetta A, Di Mitri D, Santoni B, Bencovich R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer (2020) 20:485–503. doi: 10.1038/s41562-020-0281-y

37. Zhou SL, Zhou JZ, Hu QQ, Huang WX, Wang Z, Chen EB, et al. Tumor-associated neutrophils recruit macrophages and T regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology (2016) 150:1646–1658.e17. doi: 10.1053/j.gastro.2016.02.040

38. Triner D, Devenport SN, Ramakrishnan SK, Ma X, Frieler RA, Greenau JK, et al. Neutrophils restrict tumor-associated microbiota to reduce growth and invasion of colon tumors in mice. Gastroenterology (2019) 156:1467–82. doi: 10.1053/j.gastro.2018.12.003

39. Dmirtneva-Posocco O, Dzitsev A, Posocco DF, Hou V, Yuan W, Thovarai N, et al. Cell-Type-Specific responses to interleukin-1 control microbial invasion and tumor-associated inflammation in colorectal cancer. Immunity (2019) 50:166–170.e6. doi: 10.1016/j.immuni.2018.11.015

40. Finigueru V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AA, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature (2015) 522:349–53. doi: 10.1038/nature14407

41. Ayoub NM, Jaradat SK, Al-Shami KM, Alkhalifa AE. Targeting angiogenesis in breast cancer: Current evidence and future perspectives of novel anti-angiogenic approaches. Front Oncol (2019) 9:4021655. doi: 10.3389/fonc.2019.021655

42. Bergers G, Brekken R, McMahon G, Vu TH, Isho T, Tamaki K, et al. Matrix metalloproteinase 9 triggers the angioinvasive switch during carcinogenesis. Nature Cell Biol (2000) 2:737–44. doi: 10.1038/35036374

43. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. PLoS One (2015) 10:e0121160. doi: 10.1371/journal.pone.0121160

44. Bausch D, Paulsch T, Kraus T, Hopt UT, Fernandez-del-Castillo C, Warshaw AL, et al. Neutrophil granulocyte derived MMP-9 is a VEGF-independent functional component of the angioinvasive switch in pancreatic ductal adenocarcinoma. Angiogenesis (2011) 14:235–43. doi: 10.1007/s10456-011-9207-3
Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic microenvironment modulation in cancer immunotherapy.

Ther (2015) 22:326

autophagy and neutrophil extracellular traps in pancreatic cancer.

liver metastasis.

subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer.

Frontiers in Oncology frontiersin.org

Jiang et al. 10.3389/fonc.2022.1025805

Front Immunol

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases.

Cell Rep (2021) 23:e21. doi:10.1017/erm.2021.26

targeted therapy and immunotherapy for pancreatic cancer.

KO, et al. Resistance to gemcitabine in pancreatic ductal adenocarcinoma.

doi: 10.1002/ijc.28770

expression in pancreatic ductal adenocarcinoma.

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) exert deleterious effects on immunotherapy.

Cancer Discovery (2016) 6:852–69. doi: 10.1158/2162-402X.CD-15-1777

Murray ER, Menezes S, Henry JC, Williams JL, Alba-Castello L, Baskaran P, et al. Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion. Cell Rep (2022) 38:110227. doi: 10.1016/j.celrep.2021.110227

Wang X, Yuan X, Su Y, Hu J, Iq F, Su S, et al. Targeting purinergic receptor P2RX1 mediates intestinal microbiota and alleviates inflammation in colitis. Front Immunol (2021) 12:696766. doi: 10.3389/fimmu.2021.696766

Wang X, Hu LP, Qin WT, Yang Q, Chen DY, Li Q, et al. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Nat Commun (2022) 13:2174. doi:10.1038/s41467-020-20447-y

Cuartadillo A, Rojo AL, Wells G, Hayes JD, Cousin SP, Rumsey WL, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Dev (2019) 18:295–317. doi:10.1038/s41573-018-0008-x

Boone BA, Orlichenko L, Schapiro NI, Loughran P, Gianfrate GC, Ellis JT, et al. The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Cancer Gene Ther (2015) 22:326–34. doi: 10.1038/ctg.2015.21

Kajioki H, Kagawa S, Ito A, Yoshimoto M, Sakamoto K, Kikuchi S, et al. Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. Cancer Lett (2021) 497:1–13. doi:10.1016/j.canlet.2020.01.015

Chao T, Furtth EE, Vonderheide RH. CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma. Cancer Immunol Res (2016) 4:968–82. doi: 10.1158/2326-6066.CIR-16-0188

Johnson DB, Nebljan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol (2022) 19:254–65. doi:10.1038/d41571-022-00600-w

Zhang Y, Chandra V, Riquelme Sanchez E, Dutta P, Quesada PR, Rakoski A, et al. CD11bhi neutrophil-like myeloid-derived suppressor cells exert immunosuppressive effects by arginase 1 expression in pancreatic ductal adenocarcinoma. Oncology Immunology (2017) 6: e1258504. doi:10.1016/j.oncoimm.2016.1258504

Mishalain I, Bayuh R, Eruslanov E, Michaeli J, Levy L, Zolotarov L, et al. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17—a new mechanism of impaired antitumor immunity. Int J Cancer (2013) 135:1178–86. doi: 10.1002/ijc.27770

Kolthi T, Reshkhin SJ, Carvalho TMA, Di Molfetta D, Greco MR, Alfaroak KO, et al. Resistance to gemcitabine in pancreatic ductal adenocarcinoma: A physiopathologic and pharmacologic review. Cancers (Basel) (2022) 14:2486. doi:10.3390/cancers140602486

Gao D, Song Q, Li J, Jiang Y, Wang Z, Lu S. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer. Expert Rev Med Mol Ther (2021) 23:e21. doi:10.1017/erm.2021.26

Bovin G, Ancey PB, Vuilleroyle de Silly R, Kalambaden P, Contact C, Petit B, et al. Anti-Ly6G binding and trafficking mediate positive neutrophil selection to unleash the anti-tumor efficacy of radiation therapy. Oncoimmunology (2016) 5: e1001879. doi:10.1080/2162402X.2016.1097795

Bule P, Aguiar SJ, Aires-da-Silva F, Dias JRK. Chemokine-directed tumour microenvironment modulation in cancer immunotherapy. Int J Mol Sci (2021) 22:9904. doi: 10.3390/ijms22189904
epidemiological and biological issues.

Br J Cancer pancreatic cancer and hypercoagul ability: a comprehensive review on Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice exposing blood cells, microparticles and neutrophil extracellular traps increases thrombosis.

neutrophil extracellular traps: A potential contributor to cancer-associated formation.

procedures of diphenyleneiodonium chloride addition affect neutrophil extracellular trap systematic review and meta-analysis.

Hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A Antibiotics modulate the ability of neutrophils to release neutrophil extracellular

pancreatic cancer patients with type 2 diabetes.

Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression.

Cell Commun Signal (2020) 18:52. doi: 10.1007/s12964-020-0517-1

Alekseeva LA, Senkova AV, Zenkova MA, Mironova NL. Targeting circulating SINEs and LINES with DNase I provides metastasis inhibition in experimental tumor models. Mol Ther Nucleic Acids (2020) 20:50–61. doi: 10.1016/j.ymthe.2020.01.035

Takesue S, Ouchida K, Shinkawa T, Otsubo Y, Matsumoto S, Sagara A, et al. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer-associated fibroblasts. Int J Oncol (2020) 56:596–605. doi: 10.3892/ijo.2019.4951

Xu R, J Z, Xu C, Zhu J. The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis. Med (Baltimore) (2018) 97:e12912. doi: 10.1097/MD.00000000000012912

Manda-Handzik A, Bystrzycka W, Sieczkowska S, Demkow U, Ciepiela O, Reznick AZ, Demkow U. Different procedures of diphenyleneiodonium chloride addition affect neutrophil extracellular trap formation. Anal Biochem (2016) 509:60–6. doi: 10.1016/j.ab.2016.05.003

Campello E, Bich S, Simoni P, Key NS. The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. Br J Cancer (2019) 121:359–71. doi: 10.1038/s41416-019-0510-x

Abdel Razak N, Elskalani O, Metheram P. Pancreatic cancer-induced neutrophil extracellular traps: A potential contributor to cancer-associated thrombosis. Int J Mol Sci (2017) 18:487. doi: 10.3390/ijms18030487

Yu M, Li T, Li B, Liu Y, Wang L, Zhang J, et al. Phosphatidylserine-exposing blood cells, microparticles and neutrophil extracellular traps increase procoagulant activity in patients with pancreatic cancer. Thromb Res (2020) 188:5–16. doi: 10.1016/j.thromres.2020.01.025

Hidasya Y, Grover SP, Maqbool A, Houston R, Ay C, Nouboussie DF, et al. Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. Haematologica (2020) 105:218–25. doi: 10.3324/haematol.2019.217083

Boone BA, Murphy F, Miller-Ocun J, Doerfler WR, Ellis JT, Liang X, et al. Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. BMC Cancer (2018) 18:678. doi: 10.1186/s12885-018-4584-2

Karnevi E, Sasoar A, Hilmersson KS, Ansari D, Erjefält JS, Rosendahl AH, et al. Intratumoural leukocyte infiltration is a prognostic indicator among pancreatic cancer patients with type 2 diabetes. Pancreatology (2018) 18:85–93. doi: 10.1016/j.pan.2017.11.003

Burford KG, Zhu X, Norgard MA, Levasseur PR, Huismann C, Buenafe AC, et al. Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer. Elife (2020) 9:e54095. doi: 10.7554/eLife.54095.1a2

Esser N, Legrand-Poels S, Piette J, Scheen AJ, Pasquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract (2014) 105:141–50. doi: 10.1016/j.diabres.2014.04.006

Brooks-Worrell B, Nacler L, Palmer JP. Biomarkers and immune-modulating therapies for type 2 diabetes. Trends Immunol (2012) 33:546–53. doi: 10.1016/j.it.2012.07.002

Sosals D, Vucic E, Kurz F, Hajdu C, Bar-Sagi D. Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy. Cell Rep (2021) 36:109578. doi: 10.1016/j.celrep.2021.109578

Zhang Z, Shang J, Dai Z, Yao Y, Shi Y, Zhong D, et al. Transmembrane protein 170B is a prognostic biomarker and associated with immune infiltrates in pancreatic adenocarcinoma. Front Genet (2022) 13:848391. doi: 10.3389/fgene.2022.848391

Bellomo G, Rainer C, Quaranta V, Astuti Y, Raymunt M, Boyd E, et al. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Gut (2022) 71(11):2284–99. doi: 10.1136/gutjnl-2021-325272

Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, et al. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody. Clin Cancer Res (2017) 23:2942–50. doi: 10.1158/1078-0432.CCR-16-1794

El-Maissi F, Fakhoury I, Al Haddad M, Noaha S, Abi-Habb R, El-Sibai M. Human reconstitute arbinogene 1 [HuArgI(Co)-PEG5000]-Induced arginine depletion inhibits pancreatic cancer cell migration and invasion through autophagy. Pancreas (2021) 50:1187–94. doi: 10.1097/MPA.0000000000001891

Su YL, Banerjee S, White SV, Kortylewski M. STAT3 in tumor-associated myeloid cells: Multiskating to disrupt immunity. Int J Mol Sci (2018) 19:1803. doi: 10.3390/ijms19061803

Li Y, Zhao W, Wang Y, Wang H, Liu S. Extracellular vesicle-mediated crosstalk between pancreatic cancer and stromal cells in the tumor microenvironment. J Nanobiotechnol (2020) 20:208. doi: 10.1186/s12951-022-01382-0

Sun W, Ren Y, Liu Z, Zhao X. The potential roles of exosomes in pancreatic cancer initiation and metastasis. Mol Cancer (2020) 19:135. doi: 10.1186/s12943-020-01255-w

Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer (2020) 20:516–31. doi: 10.1038/s41465-020-0273-y

Wang L, Liu Y, Dai Y, Tang X, Yin T, Wang C, et al. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut (2022) gutjnl-2021-326070. doi: 10.1136/gutjnl-2021-326070

Lin Y, Chen Y, Feng W, Zhang J, Hua R, Yin B, et al. STAT5 promotes chronic pancreatitis by enhancing GM-CSF-dependent neutrophil augmentation. J Leukoc Biol (2021) 110:293–308. doi: 10.1002/jlb.2020-0477R

Steele CW, Karim SA, Forth M, Bishi L, Leach JD, Porter RJ, et al. CXCR2 inhibition suppresses acute and chronic pancreatic inflammation. J Pathol (2015) 237:85–97. doi: 10.1002/path.4555

Mürezzani R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med (2012) 366:489–91. doi: 10.1056/NEJMmp1114866